AstraZeneca said on Friday (20) that its cocktail of AZD7442 antibodies significantly reduced the incidence of symptomatic cases of covid-19 during phase 3 clinical trials. The drugmaker, which makes vaccines against covid-19, said that prophylactic tests fulfilled the goal of preventing the disease, and reduced the risk of patients developing symptomatic cases by 77%. “There were no serious cases of covid-19 or deaths caused by covid among people treated with AZD7442. Among those who received placebos, there were three serious cases of covid-19, including two deaths,” the company said.
AstraZeneca said the data show that the cocktail may help people for whom vaccines are not enough to return to normal life, and that preliminary findings show that the antibodies “neutralize newly emerging variants of SARS-CoV-2, including the Delta variant”. Source: Dow Jones Newswires.
The post AstraZeneca: cocktail reduces the risk of symptomatic covid-19 cases by 77% appeared first in ISTOÉ DINHEIRO.